Valuation: Inhalation Sciences Sweden AB

Market Cap 92.16L 10L 8L 8L 7L 13.56L 9.22Cr 13.77L 36.17L 4.59Cr 36.29L 35.49L 15Cr P/E 2024
-12.8x
P/E 2025 -12.4x
Enterprise Value 63.85L 7L 6L 5L 5L 9L 6.39Cr 10L 25.06L 3.18Cr 25.14L 24.59L 11Cr EV / Sales 2024
5.6x
EV / Sales 2025 55x
Free-Float
94.25%
Yield 2024 *
-
Yield 2025 -
1 day-16.67%
1 week-19.28%
1 month-12.62%
3 months-23.73%
6 months-55.00%
Current year-95.85%
1 week 0.18
Extreme 0.18
0.23
1 month 0.18
Extreme 0.18
0.25
Current year 0.17
Extreme 0.172
0.58
1 year 0.17
Extreme 0.172
0.58
3 years 0.17
Extreme 0.172
4.99
5 years 0.17
Extreme 0.172
11.3
10 years 0.17
Extreme 0.172
15.48
Manager TitleAgeSince
Chief Executive Officer - 16/09/2019
Chief Tech/Sci/R&D Officer - 01/01/2005
Corporate Officer/Principal - 02/06/2025
Director TitleAgeSince
Director/Board Member - 01/01/2005
Director/Board Member - 01/09/2022
Director/Board Member - 01/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
-16.67%-19.28%-95.85%-93.92% 10L
-0.43%+1.06%+24.03%+5.21% 21TCr
-0.61%+1.82%-1.07%-23.54% 14TCr
+0.10%+4.69%-26.86%+9.07% 12TCr
+1.59%+5.60%-55.67%-9.94% 6.95TCr
-0.98%+4.16%+8.50%+4.90% 4.96TCr
-0.91%+5.13%-20.61%-29.50% 4.72TCr
-0.25%-0.14%+21.91%+12.97% 3.91TCr
-0.79%+0.70%+29.97%+37.50% 3.7TCr
+0.00%+5.67%+116.67%+8.35% 3.1TCr
Average -1.90%+0.90%+0.10%-7.89% 7.48TCr
Weighted average by Cap. -0.24%+2.77%+3.70%-0.90%

Financials

2024 2025
Net sales 1.1Cr 11.58L 10.07L 9L 9L 16.25L 11Cr 16.5L 43.36L 5.5Cr 43.5L 42.54L 18Cr 30.41L 3L 3L 3L 2L 4L 3.04Cr 5L 11.93L 1.52Cr 11.97L 11.71L 5.08Cr
Net income -51.47L -5L -5L -4L -4L -8L -5.15Cr -8L -20.2L -2.56Cr -20.27L -19.82L -8.6Cr -1.02Cr -10.65L -9L -9L -8L -14.94L -10Cr -15.18L -39.87L -5.06Cr -40.01L -39.13L -17Cr
Net Debt -40.03L -4L -4L -3L -3L -6L -4.01Cr -6L -15.71L -1.99Cr -15.76L -15.42L -6.69Cr -28.31L -3L -3L -2L -2L -4L -2.83Cr -4L -11.11L -1.41Cr -11.15L -10.9L -4.73Cr
Logo Inhalation Sciences Sweden AB
Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.
Employees
5
Date Price Change Volume
31/26/31 SEK 0.1800 -16.67% 3,70,147
29/26/29 SEK 0.2160 -1.82% 2,48,550
28/26/28 SEK 0.2200 -3.08% 1,027
27/26/27 SEK 0.2270 +1.79% 64,459
24/26/24 SEK 0.2230 -0.45% 1,17,473

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISAB Stock